X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 46c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of $0.45, $0.46 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $15.27 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• SEGG Media sues short seller for $20M over stock report
• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story